Latest News

The multi-target collaboration will integrate Insilico’s proprietary Pharma.AI platform with Bora’s automated manufacturing and development capabilities to establish a next-generation model for drug innovation.

The assistance forms part of a wider U.S.-Madagascar health partnership established under the bilateral Global Health Memorandum of Understanding (MOU) signed in December 2025.

The approval marks the first oral PCSK9 inhibitor, offering patients an alternative to injectable therapies traditionally used to reduce LDL cholesterol levels.

Fabhalta, a first-in-class complement factor B inhibitor, initially received accelerated FDA approval in 2024 to reduce proteinuria, or excess protein in the urine, a key indicator of kidney damage.

Samsung Biologics is pursuing the acquisition as demand for peptide therapeutics continues to accelerate, particularly amid the global success of GLP-1 medicines for treating obesity and type 2 diabetes.

The EBO-PEP platform trial, which has been under development since 2024, will evaluate several medicines as post-exposure prophylaxis for people who have had high-risk contact with filoviruses, the virus family that includes Bundibugyo Ebola.

The signing ceremony brought together National Treasury and Economic Planning Cabinet Secretary John Mbadi, U.S. Chargé d’Affaires Susan Burns, Health Cabinet Secretary Aden Duale, senior government officials and representatives from both countries.

The launch includes eight hospital-grade hemodialysis concentrate solutions designed to support the treatment of patients living with kidney failure.

The transaction, announced on July 3, includes Tanabe Pharma Factory’s production facilities in Onoda and Yoshitomi.

The study will use the Dexcom G7 Continuous Glucose Monitoring system, developed by a global leader in CGM technology, to assess whether continuous monitoring can improve blood sugar control when integrated into a structured, multidisciplinary care programme.